Alisporivir is primarily investigated for its antiviral properties, particularly in the treatment of chronic hepatitis C virus (HCV) infection. It functions by targeting cyclophilin A, a host protein essential for HCV replication, thereby inhibiting the virus's ability to proliferate. This mechanism offers a promising alternative to direct-acting antivirals, especially in cases of drug resistance. Additionally, Alisporivir has shown potential in treating other viral infections, such as dengue and coronavirus, due to its broad-spectrum antiviral activity. Its role in reducing inflammation and fibrosis in liver diseases further highlights its therapeutic versatility. Clinical trials continue to explore its efficacy and safety in various medical applications.